Internal Reference Number: FOI_7917
Date Request Received: 03/05/2024 00:00:00
Date Request Replied To: 10/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: • Adalimumab – Humira <5 • Adalimumab Biosimilar 29 • Apremilast <5 • Bimekizumab <5 • Brodalumab 8 • Certolizumab <5 • Deucravacitinib 0 • Dimethyl fumarate 0 • Etanercept – Enbrel 0 • Etanercept Biosimilar 0 • Guselkumab 11 • Infliximab – Remicade 0 • Infliximab Biosimilar 0 • Ixekizumab 5 • Risankizumab 7 • Secukinumab <4 • Tildrakizumab 9 • Ustekinumab 14 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following: • Adalimumab - Humira • Adalimumab Biosimilar • Bimekizumab • Certolizumab • Infliximab - Remicade • Infliximab Biosimilar • Secukinumab • Ustekinumab | |
| Answer To Question 2: Adalimumab biosimilar <5 Zero for all the other biologics listed. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¿´Æ¬Èí¼þ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
